

Cosentyx Rheum - Mechanism of action - HCP

[Prescribing information](#)

Image



Image



## **Cosentyx® (secukinumab): Mechanism of action**

Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs; active enthesitis-related

arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.<sup>1,2</sup>

## Cosentyx blocks IL-17A, a key cytokine associated with inflammation in PsA, axSpA and JIA<sup>1-12</sup>

Image



Increased levels of IL-17A are found in the tissues of:

- PsA patients with psoriatic plaques<sup>1,2</sup>
- blood of patients with **PsA and AS**<sup>8,15</sup>

Image




IL-17A is a pro-inflammatory cytokine. Its overproduction may contribute to signs and **symptoms seen in patients with PsA, AS, and nr-axSpA**<sup>1,2,12,16</sup>

## Cosentyx blocks IL-17A, irrespective of its source<sup>1,2,13,14</sup>

[Watch the video](#) below to discover how Cosentyx works.

Image



## How does Cosentyx work?



This video has been produced and funded by Novartis Pharmaceuticals Ltd.  
Intended for UK healthcare professionals only.

September 2023 | 286183

**VIDEO**

---

Image



**Efficacy in PsA**

Image



**Efficacy in axSpA**

Image



**Efficacy in JIA**

Image



**Dosing**

Image



**Safety profile**



Image



**HCP resources**

---

**Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Please refer to the Cosentyx SmPC for full product information before prescribing.**<sup>1,2</sup>

**Therapeutic Indications**<sup>1,2</sup>

Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have

responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.<sup>1,2</sup>

AS, ankylosing spondylitis; axSpA, axial spondyloarthritis; CRP, C-reactive protein; DMARD, disease modifying anti-rheumatic drug; ERA; enthesitis-related arthritis; HS, hidradenitis suppurativa; IL-17A, interleukin 17A; IL-23, interleukin 23; JIA, juvenile idiopathic arthritis; MRI, magnetic resonance imaging; MTX, methotrexate; NK, natural killer; nr-axSpA, non-radiographic axial spondyloarthritis; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis; PsO, plaque psoriasis; SmPC, Summary of Product Characteristics; TNF $\alpha$ , tumour necrosis factor alpha.

## References

1. Cosentyx® (secukinumab) GB Summary of Product Characteristics.
2. Cosentyx® (secukinumab) NI Summary of Product Characteristics.
3. Smith JA & Colbert RA. *Arthritis Rheumatol* 2014;66(2):231–241.
4. Cua DJ, et al. *Nat Rev Immunol* 2010;10(7):479–489.
5. Baeten D, et al. *N Engl J Med* 2015;373(26):2534–2548.
6. Mease PJ, et al. *N Engl J Med* 2015;373(14):1329–1339.
7. McInnes IB, et al. *Lancet* 2015;386(9999):1137–1146.
8. Mills KHG. *Nat Rev Immunol* 2023;23(1):38–54.
9. Raychaudhuri SP & Raychaudhuri SK. *Arthritis Res Ther* 2017;19(1):51.
10. Paroli M, et al. *Medicina* 2022;58:1552.
11. Lubberts E. *Nat Rev Rheumatol* 2015;11(7):415–429.
12. Deodhar A, et al. *Arthritis Rheumatol* 2021;73(1):110–120.

13. Schön M & Erpenbeck L. *Front Immunol* 2018;9:1323.
14. Gorelick J, et al. *Practical Dermatol* 2016;12:35–50.
15. Tsukazaki H & Kaito T. *Int J Mol Sci* 2020;21(17):6401.
16. Miossec P & Kolls JK. *Nat Rev Drug Discov* 2012;11(10):763–776.

UK | October 2024 | 449390

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

**Source URL:** <https://prod.pro.novartis.com/uk-en/medicines/rheumatology/cosentyx/moa>